Akoya Biosciences (AKYA) and SAMBAI announced that Akoya’s PhenoCycler-Fusion system will be the foundational spatial proteomics technology ...

Breast, pancreatic, and prostate cancers have a disproportionately higher rate of aggressive tumor grade in the target ...

Quanterix sees growth with Akoya acquisition, but rising losses and investor skepticism persist. Explore challenges and ...

Akoya Biosciences, Inc. (NASDAQ:AKYA – Get Free Report) saw a large decline in short interest in March. As of March 15th, there was short interest totalling 2,490,000 shares, a decline of 30.8% from ...

Fintel reports that on March 25, 2025, Stephens & Co. downgraded their outlook for Akoya Biosciences (NasdaqGS:AKYA) from ...

Akoya Biosciences (NASDAQ:AKYA – Get Free Report) is projected to post its quarterly earnings results after the market closes on Monday, March 31st. Analysts expect Akoya Biosciences to post earnings ...

Tikvah Management, which owns approximately 1.5% of the outstanding common shares of Quanterix (QTRX) intends to vote against the company’s ...

Akoya Biosciences (AKYA) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to loss of $0.22 per share a year ago. These ...

Highlights of the presentation include: The Transaction is a bad deal for Quanterix shareholders – The Transaction inexplicably values Akoya nearly 5x higher than Quanterix, despite Quanterix ...

MARLBOROUGH, Mass. (AP) — MARLBOROUGH, Mass. (AP) — Akoya Biosciences Inc. (AKYA) on Monday reported a loss of $8.2 million in its fourth quarter. On a per-share basis, the Marlborough, ...